Navigation Links
EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Date:5/30/2008

nology includes the United States: US FDA and University of California Davis. Asia: Hiyoshi Corporation of Japan, Cheng-Shiu University, Taiwan. Europe: Scientific Institute of Public Health, Brussels, Belgium, Federal Feed Laboratory, Tervuren, Belgium, and the National Veterinary Research Institute, Pulawy, Poland.

Development of the XDS-CALUX(R) technology was funded in part by Superfund Basic Research Program Grant (ES04699), and by Small Business Innovation Research Grants from the National Institute of Environmental Health Sciences (ES 08372-01 and ES 08372-02).

Additional information: XDS (http://www.dioxins.com) or call 1-888-D-I-O-X-I-N-S

(R) "Registered US Trademark and Patent Office"


'/>"/>
SOURCE Xenobiotic Detection Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email: